European Journal of Cancer
Volume 46, Issue 1 , Pages 6-8 , January 2010

Biomarkers of response to angiogenesis inhibitors: An open and unsolved question

Received 6 October 2009 ,Accepted 16 October 2009.

References 

  1. Nico B, Benagiano V, Mangieri D, et al. Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol. 2008;23:691–697
  2. Martin-Padura I, Bertolini F. Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci. 2009;1:304–318
  3. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111:1201–1207
  4. Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res. 2002;22:1877–1880
  5. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643–2650
  6. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92:1329–1336
  7. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792–3803
  8. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol. 2005;16:558–565
  9. Kuenen BC, Levi M, Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Clin Oncol. 2003;21:2192–2198
  10. Dowlati A, Robertson K, Radivoyevitch T, et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res. 2005;11:7938–7944
  11. DeVore RF, Hellerqvist CG, Wakefield GB, et al. Phase I study of the antineovascularization drug CM101. Clin Cancer Res. 1997;3:365–372
  12. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006;28:720–728
  13. Dobrucki LW, Sinusas AJ. Imaging angiogenesis. Curr Opin Biotech. 2007;18:1–7
  14. Mulder WJ, van der Schaft DW, Hautvast PA, et al. Early in vivo assessment of angiostatic therapy afficacy by molecular MRI. FASEB J. 2007;21:378–383
  15. Klibanov AL. Ligand-carrying gas-filled microbubbles: ultrasound agents for targeted molecular imaging. Bioconjug Chem. 2005;16:9–17
  16. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001;97:3658–3661
  17. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105:3286–3294
  18. Fürstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94:524–531
  19. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006;108:452–459
  20. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–4346
  21. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haemopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat Rev Cancer. 2002;2:826–835
  22. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001;61:4341–4344
  23. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 2003;9:377–382
  24. Taylor M, Rössler J, Geoerger B, et al. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res. 2009;15:4561–4571
  25. Vroling L, van der Veldt AA, de Haas RR, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis. 2009;12:69–79
  26. Greenfield JP, Jin DK, Young LM, et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery. 2009;64:819–826
  27. Rabascio C, Muratori E, Mancuso P, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004;64:4373–4377
  28. Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res. 2006;12:4859–4866
  29. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007;110:534–542

PII: S0959-8049(09)00780-1

doi: 10.1016/j.ejca.2009.10.022

European Journal of Cancer
Volume 46, Issue 1 , Pages 6-8 , January 2010

Article Tools